CovalX

CovalX has been established as the leader in characterizing protein interactions by mass spectrometry. Providing Innovative Technologies and Exclusive Services, CovalX has been doing business with world-renowned Universities, therapeutic companies, and most major pharmaceutical companies worldwide for many years. CovalX AG developed a unique protocol for measuring intact protein complexes using MALDI mass spectrometry. CovalX both sells the tools and/or services for High-Mass MALDI protein-protein interaction analysis. The main applications involve: epitope mapping (both conformational or linear) characterizing aggregates from biotherapeutic drugs analyzing antibody-antigen interactions rapid characterization of any protein complexes (stoichiometry, inhibition, etc) CovalX also has flexibility and provides...

Protein complex,therapeutic aggregates or aggregation,antibody characterization,high mass protein,protein:protein interactions - ppi,amino acids,enzymes,monoclonal antibody,de novo sequencing,hdx-ms,xl-ms,intact maldi-ms,mab characterization,epitope mapping services,epitope mapping,large molecules,conformational analysis by hdx-ms,spr analysis,pmf analysis,ptm analysis,ich-q6b analysis,disulfide mapping,and biotherapeutics

Covalx operates in the Biotechnology research industry.

Covalx's revenue is 11m - 100m

Covalx has 11 - 50 employees.